Saltar al contenido principal
amavitaRESEARCH

FOR PATIENTS - MIAMI

Tomorrow's Heart Treatments -- Available to You at No Cost, in Miami, Today.

Seven active cardiovascular studies. Bilingual coordinators (English and Spanish). World-class investigators. All study-related visits, study medication, and procedures at no cost -- many trials also pay for your time and travel. Apply in 60 seconds and we will call you back the same business day.

Referral partner: Larkin Hospital / Same-day callback / $0 study cost / Bilingual EN-ES

Find My Trial (60-second screening)Call (786) 537-4559

Espanol

Larkin Hospital Referral Partnership

Patients are referred from and supported by our hospital partner network for seamless, continuity-focused care during participation.

HypertensionHFrEFHFpEFACSPADIron-Deficiency HF
Advanced Cardiovascular of Miami catheterization lab
Affiliated Surgery Center

Advanced cardiovascular care in a comfortable, same-day setting

The only ambulatory surgery center of its kind in South Florida.

All trial-related procedures are performed at our affiliated state-of-the-art surgical center in Miami — the only one of its kind in South Florida — so you receive advanced cardiovascular care in a comfortable, same-day outpatient setting.

9408 SW 87th Ave., Suite 303, Miami, FL 33176

Showing 7 of 7 trials

Phase 3Hypertension● Currently Recruiting

ZENITH — Zilebesiran (RNAi)

Treatment-Resistant Hypertension

Protocol: Alnylam ALN-AGT01-008

Phase 3 evaluation of zilebesiran, an investigational RNAi therapeutic targeting AGT, for adults with treatment-resistant hypertension and elevated cardiovascular risk.

Sponsor: Alnylam Pharmaceuticals · PI: Dr. William W. O'Neill, MD, FACC (Senior PI)

Key Eligibility

  • Adults 18+ with treatment-resistant hypertension
  • Currently on ≥3 antihypertensive medications
  • Elevated cardiovascular risk profile
Apply for this trial
Phase 3ACS● Currently Recruiting

Librexia ACS

Acute Coronary Syndrome

Protocol: Pfizer C4921003

Pivotal Phase 3 study evaluating a novel antithrombotic strategy in patients following an acute coronary syndrome event.

Sponsor: Pfizer

Key Eligibility

  • Adults with recent ACS event
  • Clinically stable for randomization
  • On standard-of-care therapy
Apply for this trial
Phase 2Heart FailureRecruiting

JK07 — Heart Failure

Heart Failure (across EF ranges)

Protocol: JK07201

Novel heart failure therapy under investigation across the spectrum of ejection fraction, including HFrEF, HFmrEF, and HFpEF.

Sponsor: JK07 Bio

Key Eligibility

  • Adults 18–85 with chronic heart failure
  • NYHA Class II–III symptoms
  • On stable guideline-directed medical therapy
Apply for this trial
Phase 3Heart FailureRecruiting

IV Ferric Derisomaltose

Iron-Deficient Heart Failure

Phase 3 evaluation of intravenous ferric derisomaltose in patients with heart failure and iron deficiency to improve outcomes and quality of life.

Sponsor: Pharmacosmos

Key Eligibility

  • Adults with HFrEF or HFpEF
  • Confirmed iron deficiency (TSAT <20% or ferritin criteria)
  • Stable on guideline-directed therapy
Apply for this trial
Phase 1Heart FailureEnrolling Soon

Phase 1 HFpEF — VS-041

HFpEF

First-in-human evaluation of VS-041, a novel mechanism targeting cardiac structural remodeling in heart failure with preserved ejection fraction.

Sponsor: VASA Therapeutics

Key Eligibility

  • Adults 40–80 with NYHA Class II–III HFpEF
  • LVEF ≥ 50%
  • Elevated NT-proBNP
Apply for this trial
Phase 2Heart FailureRecruiting

HFpEF — PF-07328948

HFpEF (Metabolic Therapy)

Metabolic-pathway therapy under investigation for symptomatic improvement in heart failure with preserved ejection fraction.

Sponsor: Pfizer

Key Eligibility

  • Adults with confirmed HFpEF
  • BMI ≥ 27
  • Stable cardiovascular medications ≥ 30 days
Apply for this trial
Phase 3VascularRecruiting

Golazo® GREAT — Peripheral Atherectomy

Peripheral Artery Disease

Pivotal evaluation of an advanced peripheral atherectomy system for treatment of calcified lower-extremity arterial disease.

Sponsor: Cardiovascular Systems Inc.

Key Eligibility

  • Adults 18+ with symptomatic PAD
  • Rutherford Class 2–4
  • Suitable target lesion on imaging
Apply for this trial

FAQ

Frequently Asked Questions

Common questions from patients exploring clinical trial participation at Amavita Research.